CSPC Pharmaceutical Group Limited
CSPCYOTCHealthcare● Active
$3.64
+$0.00(+0.00%)
Market Cap$10.5B
P/E Ratio—
52W High$5.83
52W Low$3.45
CSPC Pharmaceutical Group Limited (CSPCY) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CSPCY · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $25.29B | $28.99B | $34.60B | $30.94B | $27.90B |
| Cost of Revenue | $8.70B | $8.71B | $10.20B | $8.68B | $6.73B |
| Gross Profit | $16.59B | $20.29B | $24.40B | $22.26B | $21.14B |
| Gross Margin %(computed) | 65.59% | 69.97% | 70.51% | 71.94% | 75.76% |
| Operating Expenses | |||||
| R&D Expenses | $5.65B | $5.19B | $5.34B | $4.58B | $3.44B |
| G&A Expenses | $0.00B | $1.08B | $1.31B | $1.33B | $1.01B |
| Total Operating Expenses | $12.73B | $14.92B | $16.72B | $15.50B | $14.91B |
| Operating Income | $3.86B | $5.43B | $7.68B | $6.91B | $6.25B |
| Operating Margin %(computed) | 15.27% | 18.73% | 22.20% | 22.33% | 22.41% |
| Interest Income | $0.19B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.04B | $0.04B | $0.03B | $0.02B | $0.01B |
| Income Before Tax | $4.68B | $5.58B | $7.39B | $7.72B | $6.85B |
| Income Tax Expense | $0.91B | $1.24B | $1.32B | $1.35B | $1.16B |
| Net Income | $3.78B | $4.33B | $5.87B | $6.20B | $5.61B |
| Net Margin %(computed) | 14.93% | 14.92% | 16.98% | 20.04% | 20.11% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $1.32 | $1.48 | $2.00 | $2.04 | $1.88 |
| Wtd Avg Shares | 2.86B | 2.93B | 2.97B | 2.98B | 2.99B |
| EBITDA | $5.23B | $6.45B | $8.53B | $8.66B | $7.02B |
| EBITDA Margin %(computed) | 20.69% | 22.24% | 24.66% | 27.98% | 25.15% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · CNY · B
Explore more CSPC Pharmaceutical Group Limited data
About CSPC Pharmaceutical Group Limited (CSPCY) Income Statement
CSPC Pharmaceutical Group Limited (CSPCY) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CSPCY reported revenue of $25.29B, gross profit of $16.59B (gross margin 65.59%), and net income of $3.78B — a net profit margin of 14.93%.
Frequently asked questions
CSPCY · 4 questionsCSPC Pharmaceutical Group Limited (CSPCY) reported revenue of $25.29B for 2025, down 12.8% year-over-year.
CSPCY revenueCSPCY salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08